Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 42

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 42
---
 of the Merger Agreement and some of them hold executive positions in MIRA. Further, certain of the stockholders of MIRA also hold shares of SKNY Common Stock, and certain of such directors and officers may also serve as directors or officers of companies with whom SKNY has ongoing contractual relations. Some of such relations may create conflicts with the interests of SKNY or MIRA. For example, among the shareholders of SKNY and of MIRA are shareholders of MIRALOGIX, the licensor to SKNY of certain of SKNY’s product candidates. In some cases, such licenses obligate SKNY to pay royalties to MIRALOGIX even if SKNY is not then earning revenue on the licensed products.

The members of the MIRA Board were aware of and considered these interests in evaluating the Merger and in making the MIRA Recommendation. The interests of MIRA’s directors and executive officers are described in more detail in “ Interests of the MIRA Directors, Executive Officers and Affiliate Shareholders in the Merger”on page 31 of this proxy statement.

The completion of the Merger is not conditioned on the receipt of an opinion of counsel to the effect that the Merger will qualify for the Intended Tax Treatment, and neither MIRA nor SKNY intends to request a ruling from the Internal Revenue Service regarding the U.S. federal income tax consequences of the Merger.

It is intended that, for U.S. federal income tax purposes, the Merger will constitute the Intended Tax Treatment (as defined below). However, the completion of the Merger is not conditioned on the Merger qualifying for the Intended Tax Treatment or upon the receipt of an opinion from counsel to that effect, and whether or not the Transaction will qualify for the Intended Tax Treatment depends on facts that will not be known until the Merger is completed. Finally, neither MIRA nor SKNY intends to request a ruling from the Internal Revenue Service regarding the U.S. federal income tax consequences of the Merger. Therefore, even if MIRA concludes that the Merger qualifies for the Intended Tax Treatment, no assurance can be given that the Internal Revenue Service will not challenge that conclusion or that a court would not sustain such a challenge.

| 21 |

You should read “ Material U.S. Federal Income Tax Considerations” and consult your own tax advisors regarding the U.S. federal income tax consequences of the Merger to you in your particular circumstances.

MIRA is subject to various uncertainties, including contractual restrictions and requirements while the